Amylyx Pharmaceuticals Inc (NAS:AMLX)

$ 2.23 0.01 (0.45%) Market Cap: 151.82 Mil Enterprise Value: -154.85 Mil PE Ratio: 0 PB Ratio: 0.58 GF Score: 21/100

Q4 2023 Amylyx Pharmaceuticals Inc Earnings Call Transcript
Feb 22, 2024

$18.54 (+21.10%)

Earnings
Q3 2023 Amylyx Pharmaceuticals Inc Earnings Call Transcript
Nov 09, 2023

$12.26 (-31.89%)

Earnings
Amylyx Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2023
Q2 2023 Amylyx Pharmaceuticals Inc Earnings Call Transcript
Aug 10, 2023

$21.17 (-1.49%)

Earnings
Amylyx Pharmaceuticals Inc To Host Virtual Webcast on AMX0035 Progressive Supranuclear Palsy (PSP) Program Transcript
Jul 26, 2023
Amylyx Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript
Jun 13, 2023
Amylyx Pharmaceuticals Inc Annual Shareholders Meeting Transcript
Jun 08, 2023
Q1 2023 Amylyx Pharmaceuticals Inc Earnings Call Transcript
May 11, 2023

$28.82 (-0.41%)

Earnings
Amylyx Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 18, 2023
Amylyx Pharmaceuticals Inc at Stifel CNS Days (Virtual) Transcript
Mar 28, 2023
Q4 2022 Amylyx Pharmaceuticals Inc Earnings Call Transcript
Mar 13, 2023

$31.17 (+1.66%)

Earnings
Amylyx Pharmaceuticals Inc at SVB Securities Global Biopharma Conference (Virtual) Transcript
Feb 14, 2023
Amylyx Pharmaceuticals Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript
Nov 29, 2022
Q3 2022 Amylyx Pharmaceuticals Inc Earnings Call Transcript
Nov 10, 2022

$35.39 (+2.25%)

Earnings
Amylyx Pharmaceuticals Inc RELYVRIO™ FDA Approval Call Transcript
Sep 30, 2022
Amylyx Pharmaceuticals Inc Annual Shareholders Meeting Transcript
Jun 09, 2022

Amylyx Pharmaceuticals Inc RELYVRIO™ FDA Approval Call Transcript

Sep 30, 2022 / 12:00PM GMT

Release Date Price: $28.15 (-6.76%)

Transcript

Operator

Good morning. My name is Rocco, and I will be your conference operator today. At this time, I would like to welcome everyone to the Amylyx Pharmaceuticals RELYVRIO FDA approval Conference Call. (Operator Instructions)

Please be advised that this call is being recorded at the company's request. I would now like to turn the call over to Lindsey Allen, Head of Investor Relations and Communications. Please proceed.

Lindsey Allen

Good morning, and thank you for joining us today to discuss the FDA approval of RELYVRIO, previously known as AMX0035 in the U.S. With me on the call are co-CEOs, Josh Cohen and Justin Klee; and Margaret Olinger, Chief Commercial Officer. Chief Financial Officer, Jim Frates, will be joining us for Q&A.

Before we begin, I would like to remind everyone that some of the statements that we make on this call and information presented in the slide deck include forward-looking statements that are based on our current plans and expectations, including with respect to RELYVRIO. Actual events and results could differ materially from

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.